Chidozie Ugwumba, identified as a roughly 10% owner of Clene Inc. (NASDAQ: CLNN), executed three separate sales of Clene common stock late in March 2026, according to a Form 4 filing with the U.S. Securities and Exchange Commission. The aggregate number of shares sold was 100,997, producing total proceeds of approximately $494,012.
The first transaction took place on March 27, when Ugwumba sold 17,470 shares at $4.75 per share. A second sale occurred on March 30 for 15,536 shares at $5.10 per share. The final disposition was recorded on March 31, consisting of 67,991 shares sold at $4.88 per share. Following these dispositions, Ugwumba continues to hold 431,094 shares of Clene common stock, ownership that is reported as being held indirectly through Symbiosis II, LLC.
At the time of these filings the stock was trading at $4.93 and had declined nearly 16% over the previous week, based on InvestingPro data referenced in the filing disclosure. Clene’s market capitalization stood at $57.3 million.
The insider sales arrive amid active financing and regulatory engagement for the biotechnology company. Clene announced it raised in excess of $28 million through a registered direct offering intended to support the clinical and regulatory progress of its investigational amyotrophic lateral sclerosis (ALS) compound, CNM-Au8. That funding round counted participation from investors identified by the company, including Boxer Capital, Coastlands Capital, Vivo Capital, and certain existing insiders.
The company expects that an initial funding tranche of more than $6 million will provide capital to sustain operations into the third quarter of 2026. That runway could coincide with a pending regulatory milestone - an anticipated decision related to the company’s New Drug Application.
Separately, Clene has been granted an in-person Type C meeting with the U.S. Food and Drug Administration to discuss biomarker analyses tied to CNM-Au8. The discussion will concentrate on new analyses showing reductions in neurofilament light chain levels - a biomarker associated with neuronal injury - that appear to correlate with lower mortality risk in ALS patients. Clene says this biomarker data could support consideration of neurofilament light chain reduction as a surrogate endpoint for an accelerated approval pathway.
The company’s broader financial picture was also noted in the filing materials: InvestingPro tips flagged that Clene is consuming cash at a rapid pace and assigned the company a "WEAK" overall financial health score. The filing referenced additional analytic resources available through the InvestingPro platform, which offer further financial metrics and ProTips for subscribers.
Investors and market participants will likely weigh the insider sales alongside Clene’s recent capital raise and its regulatory interactions as the company advances CNM-Au8 through the regulatory process. The Form 4 disclosures detail the precise trade sizes and prices but do not offer commentary on the motivations behind the sales. The clinical biomarker discussions with the FDA and the secured financing represent parallel developments as Clene manages near-term funding and regulatory milestones.